Sort   by:  
 Page size 
UnknownIntraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Not available
S-EPMC8554687 | biostudies-literature
UnknownPrehospital use of magnesium sulfate as neuroprotection in acute stroke.
Not available
S-EPMC4920545 | biostudies-literature
UnknownBaseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Not available
S-EPMC8949717 | biostudies-literature
UnknownAflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Not available
S-EPMC4422053 | biostudies-literature
UnknownPlasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Not available
S-EPMC6568257 | biostudies-literature
UnknownAssociation of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Not available
S-EPMC5567793 | biostudies-literature
Sort   by:  
 Page size